Olufemi Lawal, MD
Critical Care Medicine · Wichita Falls, TXNPI 1891056099
Payments from drug & device makers
Across 759 payments — averaging $60.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$24K
- Mylan Specialty L.p.$13K
- Pfizer$1K
- AstraZeneca$1K
- Sanofi$1K
- Philips North America LLC$864
- plus $4K from 30 others
What the payments were for
- Consulting fees$1,0002%
- Speaking & faculty fees$31,36268%
- Travel & lodging$1,0522%
- Food & beverage$12,32227%
- Education$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 213 | $24,487 |
| Mylan Specialty L.p. | 98 | $12,512 |
| Pfizer | 21 | $1,334 |
| AstraZeneca | 68 | $1,294 |
| Sanofi | 51 | $1,030 |
| Philips North America LLC | 84 | $864 |
| Boehringer Ingelheim | 43 | $794 |
| Regeneron Healthcare Solutions, Inc. | 26 | $529 |
| Amgen | 25 | $455 |
| Actelion Pharmaceuticals US, Inc. | 14 | $393 |
| United Therapeutics Corporation | 13 | $289 |
| Merck | 9 | $208 |
| Novartis | 10 | $185 |
| Viatris Specialty LLC | 6 | $136 |
| Genentech USA, Inc. | 7 | $117 |
| Baxter Healthcare | 6 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $111 |
| Grifols USA, LLC | 6 | $103 |
| Johnson & Johnson | 6 | $103 |
| Sunovion Pharmaceuticals Inc. | 9 | $101 |
| ANI Pharmaceuticals, Inc. | 5 | $101 |
| Insmed, Inc. | 5 | $86 |
| AbbVie | 4 | $86 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Verona Pharma, Inc. | 4 | $78 |
| Mallinckrodt Hospital Products Inc. | 3 | $76 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Inspire Medical Systems, Inc. | 2 | $41 |
| Chiesi USA, Inc. | 2 | $30 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Electromed, Inc. | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,916 in reported general payments places this provider in the 90th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 447 | $369,588 |
| OfevNintedanib Esylate | 26 | $338,371 |
| OpsumitMacitentan | 22 | $269,566 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 238 | $176,029 |
| Fasenra PenBenralizumab | 18 | $117,787 |
| Spiriva RespimatTiotropium Bromide | 117 | $97,397 |
| TezspireTezepelumab-Ekko | 20 | $88,454 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 150 | $80,722 |
| Dupixent PenDupilumab | 17 | $69,964 |
| XolairOmalizumab | 13 | $60,092 |
| Breo ElliptaFluticasone/Vilanterol | 112 | $51,643 |
| Pirfenidone | 19 | $42,479 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $33,862 |
| EliquisApixaban | 38 | $23,009 |
| Incruse ElliptaUmeclidinium Bromide | 50 | $18,134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $794 | $516,490293 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $24,487 | $486,736701 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,294 | $278,768310 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $393 | $269,56622 claims |
| PfizerEliquis | $1,334 | $23,00938 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Wichita Falls
- Satish ChadaWichita Falls$18K
- Rafael Rivera RiveraWichita Falls$16K
- Musa WadiWichita Falls$12K
- Cynthia ZamoraSan Antonio$6.4M
- Rishi RajLubbock$1.9M
- Carlo HatemEl Paso$1.6M
- Deepa GoturHouston$1.1M
- Matt KhoshnevisHouston$759K
- Sean GilbeyAustin$723K
- Rodeo AbrencilloHouston$616K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.